These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The operable renal cell carcinoma: summary and conclusions. deKernion JB; Huland H Eur Urol; 1990; 18 Suppl 2():48-51. PubMed ID: 2226611 [No Abstract] [Full Text] [Related]
8. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. Ito K; Yoshii H; Sato A; Kuroda K; Asakuma J; Horiguchi A; Sumitomo M; Asano T J Urol; 2011 Aug; 186(2):430-5. PubMed ID: 21679988 [TBL] [Abstract][Full Text] [Related]
10. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Bromwich EJ; McArdle PA; Canna K; McMillan DC; McNicol AM; Brown M; Aitchison M Br J Cancer; 2003 Nov; 89(10):1906-8. PubMed ID: 14612901 [TBL] [Abstract][Full Text] [Related]
11. [Renal collecting duct carcinoma associated with tumor embolus in the inferior vena cava]. Guo LL; Wang MQ; Cai YR; Wang Y Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):123-4. PubMed ID: 15842816 [No Abstract] [Full Text] [Related]
12. C-reactive protein: a clinically useful biomarker in renal cell carcinoma. Johnson TV; DeLong J; Master VA JAAPA; 2012 Jan; 25(1):45-7. PubMed ID: 22384756 [No Abstract] [Full Text] [Related]
13. Prognostic Value of Inflammatory and Nutritional Scores in Renal Cell Carcinoma After Nephrectomy. Peng D; He ZS; Li XS; Tang Q; Zhang L; Yang KW; Yu XT; Zhang CJ; Zhou LQ Clin Genitourin Cancer; 2017 Oct; 15(5):582-590. PubMed ID: 28528087 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for metastatic kidney cancer. Drucker BJ; Mazumdar M; Motzer RJ Cancer Treat Res; 2003; 116():139-53. PubMed ID: 14650830 [No Abstract] [Full Text] [Related]
15. Node positive renal cell cancer. Who can be helped? Messing EM Eur Urol; 2007 Jun; 51(6):1477-8. PubMed ID: 17240037 [No Abstract] [Full Text] [Related]
16. GALNT4 predicts clinical outcome in patients with clear cell renal cell carcinoma. Liu Y; Liu W; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J J Urol; 2014 Nov; 192(5):1534-41. PubMed ID: 24769034 [TBL] [Abstract][Full Text] [Related]
17. [A clinical study of 55 cases of renal cell carcinoma]. Saito K; Iwamuro S; Fujii H; Kondo I Hinyokika Kiyo; 1989 Nov; 35(11):1847-52. PubMed ID: 2618882 [TBL] [Abstract][Full Text] [Related]
18. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550 [TBL] [Abstract][Full Text] [Related]
19. The relation between lymphocyte-monocyte ratio and renal cell carcinoma. Balta S; Demirer Z; Aparci M; Demirkol S; Ozturk C Urol Oncol; 2015 Oct; 33(10):421. PubMed ID: 26048105 [No Abstract] [Full Text] [Related]
20. [Expression of LeX antigens in renal adenocarcinoma differentiation and the prognosis]. Fukushi Y; Saito S; Orikasa S; Ohtani H Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1090-5. PubMed ID: 2903265 [No Abstract] [Full Text] [Related] [Next] [New Search]